Norvir 100 mg powder for oral suspension
Authorisation EU/1/96/016/009 · AbbVie Deutschland GmbH & Co. KG
- Licence holder
- AbbVie Deutschland GmbH & Co. KG (all products →)
- Active substance
- Ritonavir
- Clinical trials
- 3 clinical trials →
- Dosage form
- Powder for oral suspension
- Route of administration
- Oral use
- ATC codes
- J05AE, J05AE03
- First authorised
- 14/08/2015
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Ritonavir: supply and approvals
8 authorised products on the HPRA list contain Ritonavir. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 19 Nov 2026)
- US shortage (FDA)
-
Ritonavir Oral Powder: resolved, updated 24 Jul 2026
Ritonavir Tablet: resolved, updated 24 Jul 2026 - Germany (BfArM)
- 2 supply notices, e.g. Ritonavir Viatris 100 mg Filmtabletten - OP30 (12 Feb 2026 to 30 Sep 2027)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 016. It has been authorised for 11 years (since 14 August 2015). The HPRA list does not say whether it is on sale.
Other medicines with Ritonavir in Ireland
7 other products on the HPRA list contain Ritonavir, from 2 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Kaletra | AbbVie Deutschland GmbH & Co. KG | Centralised EU authorisation | Not stated |
| Kaletra (80 mg + 20 mg)/ml oral solution | AbbVie Deutschland GmbH & Co. KG | Centralised EU authorisation | Not stated |
| Kaletra 100 mg/25 mg film-coated tablets | AbbVie Deutschland GmbH & Co. KG | Centralised EU authorisation | Not stated |
| Lopinavir/Ritonavir Viatris 100 mg/25 mg film-coated tablets | Viatris Limited | Centralised EU authorisation | Not stated |
| Lopinavir/Ritonavir Viatris 200 mg/50 mg film-coated tablets | Viatris Limited | Centralised EU authorisation | Not stated |
| Norvir 100 mg film-coated tablets | AbbVie Deutschland GmbH & Co. KG | Centralised EU authorisation | Not stated |
| Ritonavir Viatris 100 mg Film-coated tablet | Viatris Limited | Centralised EU authorisation | Not stated |
Other substances in ATC group J05AE
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 6 other active substances share the group J05AE with this product:
Darunavir (16) · Atazanavir sulfate (5) · Lopinavir (4) · Darunavir (as ethanolate) (4) · Tipranavir (1) · Atazanavir (1)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
AbbVie Deutschland GmbH & Co. KG holds 37 products on the HPRA list, with 17 different active substances; 0 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 20 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.